Korean Circulation Journal

  • 제42권2호
  • /
  • Pages.86-94
  • /
  • 2012
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

The Prevalence, Awareness and Treatment of High Low Density Lipoprotein-Cholesterol in Korean Adults Without Coronary Heart Diseases - The Third Korea National Health and Nutrition Examination Survey, 2005 -

  • Choi, Sun-Ja (Division of Cardiovascular and Rare Diseases, Center for Biomedical Science, National Institute of Health) ;
  • Park, Sung-Hee (Division of Cardiovascular and Rare Diseases, Center for Biomedical Science, National Institute of Health) ;
  • Lee, Kwang-Soo (Division of Cardiovascular and Rare Diseases, Center for Biomedical Science, National Institute of Health) ;
  • Park, Hyun-Young (Division of Cardiovascular and Rare Diseases, Center for Biomedical Science, National Institute of Health)
  • 발행 : 2012.02.29
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: The purpose of this study was to estimate the prevalence, awareness and treatment of high low density lipoprotein-cholesterol (LDL-C) level in Korean adults without coronary heart disease. Subjects and Methods: National representative cross-sectional surveys, data of 5248 Korean adults (2246 men and 3002 women) aged between 20 and 79 years from the Third Korea National Health and Nutrition Examination Survey (KNHANES III, 2005) was used. High LDL-C level was defined with the risk prediction algorithm published by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). Results: The prevalence of the Korean adults with high LDL-C level who need therapeutic lifestyle changes was 19.9%, treatment with lipid-lowing medication was 2.1% and awareness of this condition was 7.9%. Meanwhile, the prevalence of the Korean with very high LDL-C level who should be considered for drug therapy was 13.5%, treatment with lipid-lowing medication was 2.7% and awareness of this condition was 8.1%. Overall, 47.9% (60.3% in male and 39.1% in female) of participants had a single lipid disorder (high LDL-C, high triglycerides: ${\geq}$200 mg/dL, low high density lipoprotein-cholesterol: <40 mg/dL), whereas 15.5% (23.5% in male and 9.7% in female) had at least two. Only 1.9% (2.8% in male and 1.2% in female) of all participants had all three lipid abnormalities as defined. Conclusion: These findings indicate that continuous efforts are needed to increase awareness and treatment of high LDL-C level in our population to prevent cardiovascular disease.

키워드

참고문헌

  1. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. https://doi.org/10.1161/01.CIR.97.18.1837
  2. Castelli WP. Epdemilology of coronary heart disease: the Framingstudy. Am J Med 1984;76:4-12. https://doi.org/10.1016/0002-9343(84)90952-5
  3. Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: finding form long-term follow-up of Chicago cohorts. Cardiology 1993;82:191-222. https://doi.org/10.1159/000175868
  4. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-8. https://doi.org/10.1001/jama.284.3.311
  5. In-Depth Analysis of the Third Korea National Health and Nutrition Examination Survey (KNHANES III). Seoul: Korea Centers for Disease Control and Prevention;2007.
  6. Lim S, Jang HC, Park HC, et al. Changes in metabolic syndrome of Korean children and adolescents in the period 1998 to 2001. J Endocrinol Invest 2008;31:327-33. https://doi.org/10.1007/BF03346366
  7. The Lipid Research Clinics Coronary Primary Prevention Trial. l. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64. https://doi.org/10.1001/jama.1984.03340270029025
  8. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousidian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835-8. https://doi.org/10.1001/jama.1986.03380200073024
  9. Frick MH, Elo O, Haapak M, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middled-aged men with dyslipidemia: safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45. https://doi.org/10.1056/NEJM198711123172001
  10. The Lipid Research Clinics Coronary Primary Prevention Trial results. ll. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74. https://doi.org/10.1001/jama.1984.03340270043026
  11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39. https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  12. Committee of treatment guideline for hypercholesterolemia. Treatment guideline for hypercholesterolemia. 2nd ed. Seoul: Korea Society of lipidology and atherosclerosis;2008.
  13. Ko M, Kim MT, Nam JJ. Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 2006;110:184-90. https://doi.org/10.1016/j.ijcard.2005.07.030
  14. Siegel D. The gap between knowledge and practice in the treatment and prevention of cardiovascular disease. Prev Cardiol 2000;3:167-71. https://doi.org/10.1111/j.1520-037X.2000.80381.x
  15. Smaha LA. The American Heart Association get with the guidelines program. Am Heart J 2004;148(5 Suppl):S46-8. https://doi.org/10.1016/j.ahj.2004.09.015
  16. Sung J, Kim SH, Kim YD, et al. Ten centers study on the present state of treatment for hypercholesterolemia in patients with coronary artery disease. Korean J Med 2005;69:371-8.
  17. Kim SH, Park JS, Zo JH, Kim MA, Kim HS. Treatment gap in the management of hypercholesterolemia in Korea: return on expenditure achieved for lipid therapy (REALITY). Korean Circ J 2006;36:593-9.
  18. June JE. Cholesterol lowering therapy in coronary artery disease: with particular reference to statins. Korean Circ J 2001;31:849-56. https://doi.org/10.4070/kcj.2001.31.9.849
  19. Kim MK, Kim HL, Min HS, et al. Changes of the lipoprotein profiles with time after discontinuation of stain therapy. Korean Circ J 2008;38:36-42. https://doi.org/10.4070/kcj.2008.38.1.36
  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
  21. Annual report on the cause of death statistics. Seoul: Korean National Statistical Office;2006.
  22. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in ATP-III defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548-55. https://doi.org/10.1016/j.annepidem.2007.01.032
  23. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008;156:112-9. https://doi.org/10.1016/j.ahj.2008.03.005
  24. Lee YW, Min WK, Lee W, et al. Risk analysis of coronary heart diseases in Korean adults by using the National Cholesterol Education Program Adult Treatment Panel III. J Clin Lab Anal 2007;21:178-82. https://doi.org/10.1002/jcla.20165
  25. Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 2007;29:1671-81. https://doi.org/10.1016/j.clinthera.2007.08.003
  26. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14. https://doi.org/10.1161/01.ATV.11.1.2
  27. Schaefer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC. Plasma-triglycerides in regulation of HDL-cholesterol levels. Lancet 1978;2:391-3.
  28. Casteli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7. https://doi.org/10.1016/0002-8703(86)90296-6
  29. Hong HS, Park JS, Ryu HK, Kim WY. The association of plasma HDLcholesterol level with cardiovascular disease related factors in Korean type 2 diabetes patients. Korean Diabetes J 2008;32:215-23. https://doi.org/10.4093/kdj.2008.32.3.215
  30. Park SH, Choi SJ, Lee KS, Park HY. Waist circumference and waist-toheight ratio as predictors of cardiovascular disease risk in Korean adults. Circ J 2009;73:1643-50. https://doi.org/10.1253/circj.CJ-09-0161
  31. Bersot T, Pépin GM, Mahley RW. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. Am Heart J 2003;146:1052-9. https://doi.org/10.1016/S0002-8703(03)00516-7
  32. National Health Insurance Corporation. Insurance standard of dyslipidemia. Avail from: http://www.nhic.or.kr/.

피인용 문헌

  1. Application of New Guidelines for the Primary Prevention of Atherosclerotic Cardiovascular Disease in a Korean Population vol.22, pp.3, 2012, https://doi.org/10.5551/jat.26682